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Abstract 
 
By meta-analyzing rare coding variants in whole-exome sequences of 
4,133 schizophrenia cases and 9,274 controls, de novo mutations in 1,077 trios, 
and copy number variants from 6,882 cases and 11,255 controls, we show that 
individuals with schizophrenia carry a significant burden of rare damaging 
variants in 3,488 genes previously identified as having a near-complete 
  
depletion of loss-of-function variants. In schizophrenia patients who also have 
intellectual disability, this burden is concentrated in risk genes associated with 
neurodevelopmental disorders. After excluding known neurodevelopmental 
disorder risk genes, a significant rare variant burden persists in other loss-of-
function intolerant genes, and while this effect is notably stronger in 
schizophrenia patients with intellectual disability, it is also seen in patients who 
do not have intellectual disability. Together, our results show that rare damaging 
variants contribute to the risk of schizophrenia both with and without 
intellectual disability, and support an overlap of genetic risk between 
schizophrenia and other neurodevelopmental disorders.  
 
Introduction 
 
Schizophrenia is a common and debilitating psychiatric illness 
characterized by positive symptoms (hallucinations, delusions, disorganized 
speech and behaviour), negative symptoms (social withdrawal and diminished 
emotional expression), and cognitive impairment that result in social and 
occupational dysfunction1,2. Operational diagnostic criteria for the disorder as 
described in the DSM-V require the presence of at least two of the core 
symptoms over a period of six months with at least one month of active 
symptoms3. It is increasingly recognized that current categorical psychiatric 
classifications have a number of shortcomings, in particular that they overlook 
the increasing evidence for etiological and mechanistic overlap between 
psychiatric disorders4.  
 
A diverse range of pathophysiological processes may contribute to the 
clinical features of schizophrenia5. Indeed, previous studies have suggested a 
number of hypotheses about schizophrenia pathogenesis, including abnormal 
pre-synaptic dopaminergic activity6, postsynaptic mechanisms involved in 
synaptic plasticity7, dysregulation of synaptic pruning8, and disruption to early 
brain development9,10. This complexity is underpinned by the varied nature of 
genetic contributions to risk of schizophrenia. Genome-wide association studies 
have identified over 100 independent loci defined by common (minor allele 
frequency [MAF] > 1%) single nucleotide variants (SNVs)11, and a recent analysis 
determined that more than 71% of all one-megabase regions in the genome 
contain at least one common risk allele12. The modest effects of these variants 
(median odds ratio [OR] = 1.08) combine to produce a polygenic contribution 
that explains only a fraction (ℎ𝑔
2 = 0.274) of the overall liability12. In addition, a 
number of rare variants have been identified that have far larger effects on 
individual risk. These are best exemplified by eleven large, rare recurrent copy 
number variants (CNVs) but evidence from whole-exome sequencing studies 
implies that many other rare coding SNVs and de novo mutations also confer 
substantial individual risk13–17. There is growing evidence that some of the same 
genes and pathways are affected by both common and rare variants7,18. Pathway 
analyses of common variants and hypothesis-driven gene set analyses of rare 
variants have begun to enumerate some of these specific biological processes, 
including histone methylation, transmission at glutamatergic synapses, calcium 
channel signaling, synaptic plasticity, and translational regulation by the fragile X 
mental retardation protein (FMRP)11,13,14,19,20. 
  
 
In addition to exploring the biological mechanisms underlying 
schizophrenia, genetic analyses can also be used to understand its relationship to 
other neuropsychiatric and neurodevelopmental disorders. For instance, 
schizophrenia, bipolar disorder, and autism (ASD) show substantial sharing of 
common risk variants21,22. Sequencing studies of neurodevelopmental disorders 
suggest that this sharing of genetic risk may extend to rare variants of large 
effect. In the largest sequencing study of ASD to date, 20 of the 46 genes and all 
six CNVs implicated (false discovery rate [FDR] < 5%) had been previously 
described as dominant causes of developmental disorders23. Furthermore, an 
analysis of 60,706 whole exomes led by the ExAC consortium identified 3,230 
genes with near-complete depletion of protein-truncating variants, and de novo 
loss-of-function (LoF) mutations identified in individuals with ASD or 
developmental disorders were concentrated in this set of “LoF intolerant” 
genes23–25. Similarly, evidence from rare variants for a broader shared genetic 
etiology between schizophrenia and neurodevelopmental disorders has begun to 
emerge. Analyses of whole-exome data provided support for an enrichment of 
schizophrenia rare variants in intellectual disability genes, and schizophrenia 
cases were also found to have a higher concentration of ultra-rare disruptive 
SNVs in the ExAC LoF intolerant genes compared to controls13,17,26.  
 
However, the contribution of these rare variants to risk in the wider 
population of individuals diagnosed with schizophrenia, including those without 
intellectual disability, remains unclear. Intriguingly, the 11 rare CNVs found to be 
highly penetrant for schizophrenia also increased risk for intellectual disability 
and other congenital defects16,27, and more recently, a meta-analysis of whole-
exome sequence data showed that LoF variants in SETD1A conferred substantial 
risk for both schizophrenia and neurodevelopmental disorders18. Concurrent 
analyses of autism whole-exome data found that de novo loss-of-function (LoF) 
mutations identified in ASD probands, particularly those that disrupt genes 
associated with neurodevelopmental disorders, were disproportionately found 
in individuals with intellectual disability23,28. These emerging results raise the 
possibility that rare schizophrenia risk variants may be concentrated in a subset 
of schizophrenia patients with co-morbid intellectual disability. Here, we present 
the one of the largest accumulation of schizophrenia rare variant data to date, 
which we jointly analyze with phenotype data on cognitive function. Using this 
data set, we attempt to identify groups of genes disrupted by schizophrenia rare 
risk variants, and determine if a subset of patients disproportionately carry 
these damaging alleles.  
 
Results 
 
Study design 
 
To maximize our power to detect enrichment of damaging variants in 
schizophrenia cases in groups of genes, we performed a meta-analysis of three 
different types of rare coding variant studies: (1) high-quality SNV calls from 
whole-exome sequences of 4,133 schizophrenia cases and 9,274 matched 
controls, (2) de novo mutations identified in 1,077 schizophrenia parent-proband 
  
trios (Figure 1), and (3) CNV calls from genotyping array data of 6,882 cases and 
11,255 controls.  The ascertainment of these samples, data production, and 
quality control were described previously18,29. All de novo mutations included in 
our analysis had been validated through Sanger sequencing, and stringent 
quality control steps were performed on the case-control data to ensure that 
sample ancestry and batch were closely matched between cases and controls 
(Online Methods).  
 
For each data type, we used appropriate methods to test for an excess of 
rare variants (Figure 1, Online Methods). In analyses of case-control SNV data, 
we applied an extension of the variant threshold burden test that corrected for 
exome-wide differences between cases and controls30. We tested all allele 
frequency thresholds below 0.1% observed in our data, and assessed statistical 
significance by permutation testing. In analyses of de novo SNV data, we 
compared the observed number of de novo mutations to random samples from 
an expected distribution based on a gene-specific mutation rate model to 
calculate an empirical P-value. For both types of whole-exome sequencing data, 
we restricted our analyses to loss-of-function variants. Finally, in analyses of 
case-control CNV data, we used a logistic regression framework that compares 
the rate of CNVs overlapping a specific gene set while correcting for differences 
in CNV size and number of genes disrupted7,19,31. To ensure our model was well 
calibrated, we restricted our analyses to small deletions and duplications 
overlapping fewer than seven genes with MAF < 0.1% (Supplementary Figure 1, 
Online Methods).  
 
We tested for an excess of rare damaging variants in schizophrenia 
patients in 1,766 gene sets (Online Methods, Supplementary Table 1, and 
detailed results below). Gene set P-values were computed using the three 
methods and variant definitions described above, and then meta-analyzed using 
Fisher’s Method to provide a single P-value for each gene set. Because we gave 
each data type equal weight, gene sets achieving significance typically show at 
least some signal in all three types of data. We observed a marked inflation in the 
quantile-quantile (Q-Q) plot of gene set P-values (Supplementary Figure 2), so 
we conducted two analyses to ensure our results were robust and not biased due 
to methodological or technical artifacts. First, we observed no inflation of P-
values when testing for enrichment of synonymous variants in our case-control 
and de novo analyses (Supplementary Figure 2). Second, we created random 
gene sets by sampling uniformly across the genome, and observed null 
distributions in Q-Q plots regardless of variant class and analytical method 
(Supplementary Figure 3). These findings suggested that our methods 
sufficiently corrected for known genome-wide differences in LoF and CNV 
burden between cases and controls, and other technical confounders like batch 
and ancestry.  
 
Rare, damaging schizophrenia variants are concentrated in LoF intolerant genes 
 
We first tested whether rare schizophrenia risk variants were 
consistently concentrated in genes defined loss-of-function intolerant across 
study design and variant type. Because some of our schizophrenia exome data 
  
was included in the ExAC database, we focused on the subset of 45,376 ExAC 
exomes without a known psychiatric diagnosis and that were not present in our 
study. From this subset, 3,488 genes were found to have near-complete 
depletion of such variants, which we defined as the LoF intolerant gene set. We 
found that rare damaging variants in schizophrenia cases were enriched in LoF 
intolerant genes (P < 3.6 × 10−10, Table 1, Figure 2), with support in case-control 
SNVs (P < 5 × 10−7; OR 1.24, 1.16-1.31, 95% CI), case-control CNVs (P = 
2.6 × 10−4; OR 1.21, 1.15 – 1.28, 95% CI), and de novo mutations (P = 6.7 × 10−3; 
OR 1.36, 1.1 – 1.68, 95% CI).  While this result was consistent with observations 
in intellectual disability and ASD24,32 the absolute effect size is smaller (e.g. de 
novos, Supplementary Figure 4 and 5). We observed no excess burden of rare 
damaging variants in the remaining 14,753 genes (Figure 2, Supplementary 
Figure 5). Furthermore, this signal was spread among many different LoF 
intolerant genes: if we rank genes by decreasing significance, the enrichment 
disappears in the case-control SNV analysis (P > 0.05) only after the exclusion of 
the top 50 genes. This suggests that the contribution of damaging rare variants in 
schizophrenia is not concentrated in just a handful of genes, but instead spread 
across many genes. 
 
Schizophrenia risk genes are shared with other neurodevelopmental disorders 
 
Given the significant enrichment of rare damaging variants in LoF 
intolerant genes in developmental disorders, autism and schizophrenia, we next 
asked whether these variants affected the same genes.  We found that autism 
risk genes identified from exome sequencing meta-analyses23 and genes in which 
LoF variants are known causes of severe developmental disorders as defined by 
the DDD study33,34 were significantly enriched for rare variants in individuals 
with schizophrenia (PASD = 9.5× 10−6; PDD = 2.3× 10−6; Table 1, Online Methods). 
Previous analyses have shown an enrichment of rare damaging variants in genes 
whose mRNA are bound by FMRP in both schizophrenia and autism35,13,32, so we 
sought to identify further shared biology by testing targets of neural regulatory 
genes previously implicated in autism32,36.  We observed enrichment of both 
such sets: promoter targets of CHD8 (P = 1.1× 10−6) and splice targets of RBFOX 
(P = 1.3× 10−5) (Table 1). We noted that some published gene lists attributed to 
same biological process differed due to choices of assay, cell type, method of 
sample extraction, and threshold of statistical significance, leading to distinct 
results in our gene set analyses. For example, we observed a significant 
enrichment in the published FMRP binding gene set based on mouse brain 
data37, but with no signal in one based on a human kidney cell line38. 
 
We also tested an additional 1,759 gene sets from databases of biological 
pathways with at least 100 genes, as we lacked power to detect weak 
enrichments in smaller sets (Online Methods). We observed enrichment of 
damaging rare variants in schizophrenia cases at FDR q < 0.05 in 35 of these 
gene sets (Supplementary Table 1, 2). These included previously implicated gene 
sets, like the NMDA receptor and ARC complexes13,14,35,37, as well as novel gene 
sets, such as genes involved in cytoskeleton (GO: 0007010), chromatin 
modification (GO:0016568), and chromatin organization (GO: 0006325). 
Furthermore, the gene sets most significantly enriched (FDR q < 0.01) for 
  
schizophrenia rare variants (Table 1) had all been previously linked to autism, 
intellectual disability, and severe developmental disorders23,32,33. Our 
enrichment results matched some of the findings from a pathway analysis of 
common risk variants in psychiatric disorders, which also implicated neuronal 
and chromatin gene sets20. However, unlike that study, we found no enrichment 
of rare variants in immune-related gene sets. 
 
We noticed that the 1,759 gene sets we tested were collectively enriched 
with LoF intolerant genes when compared to a random sampling of genes from 
the genome (Supplementary Figure 6 and 7). For some of the gene sets 
associated with schizophrenia, this over-representation was quite substantial:  
67% of the gene targets of FMRP and 74% of the genes associated with severe 
neurodevelopmental disorders are LoF intolerant. To better understand the 
consequences of this overlap on our results, we extended the gene set 
enrichment methods (Online Methods) to condition on LoF intolerance and 
brain-expression for the 35 gene sets with FDR q < 0.05 in the previous analysis 
(Supplementary Table 2). We first observed that 22 of the 35 gene sets remained 
significant even after conditioning on brain expression (Supplementary Tables 3, 
Online Methods), suggesting they represent more specific biological processes 
involved in schizophrenia. However, only known autism risk genes (P = 
4.4× 10−4) and neurodevelopmental disorder genes (P = 3× 10−5) had an excess 
of rare coding variants above the enrichment already observed in LoF intolerant 
genes (Supplementary Table 3). Thus, in addition to biological pathways 
implicated specifically in schizophrenia, at least a portion of the schizophrenia 
risk conferred by rare variants of large effect is shared with childhood onset 
disorders of neurodevelopment. 
 
Schizophrenia patients with intellectual disability have a greater burden of rare 
damaging variants 
 
In autism spectrum disorders, the observed excess of rare damaging 
variants has been shown to be greater in individuals with intellectual disability 
than those with normal levels of cognitive function28. We observed a similar 
phenomenon in schizophrenia cases carrying SETD1A LoF variants18, so next 
sought to explore whether this pattern is consistent in gene sets implicated in 
schizophrenia. We acquired relevant cognitive phenotype data for 2,971 of the 
4,131 schizophrenia patients with whole-exome sequencing data 
(Supplementary Figure 8). Of these individuals, 279 were clinically diagnosed 
with intellectual disability in addition to fulfilling the full diagnostic criteria for 
schizophrenia (SCZ-ID subgroup, Online Methods). We also identified 1,165 
individuals for whom we could rule out cognitive impairment (by excluding pre-
morbid IQ < 85, fewer than 12 years of schooling or lowest decile of composite 
cognitive measures, depending on available data, Online Methods). Finally, we 
identified 1,527 individuals who were not diagnosed with intellectual disability, 
but in whom some cognitive impairment could not be excluded.  
 
When stratifying into these three groups (intellectual disability, no 
intellectual disability but cognitive impairment not excluded, no cognitive 
impairment), we observed that the burden of rare damaging variants in LoF 
  
intolerant genes was significantly greater in the SCZ-ID subgroup than in the 
remaining schizophrenia cases (P = 2.6 × 10−4; OR 1.3, 1.12– 1.51, 95% CI) or 
controls (P < 5 × 10−7; OR 1.61, 1.37 – 1.89, 95% CI; Figure 3). In the LoF 
intolerant gene set, 0.27 (0.2 – 0.35, 95% CI) extra singleton (defined as having 
an allele count of one in our data set) LoF variants were observed per exome in 
SCZ-ID cases compared to controls, while 0.10 (0.065 – 0.13, 95% CI) extra 
singleton LoF variants per exome were observed in the remaining schizophrenia 
cases compared to controls (Online Methods).  Furthermore, SCZ-ID individuals 
had significant enrichment of rare LoF variants in developmental disorder genes 
compared to the other cases (P = 9 × 10−4; OR 2.36, 1.41– 3.92, 95% CI) or to 
controls (P = 9.5 × 10−6; OR 3.43, 2.01– 5.86, 95% CI; Figure 4). Compared to 
controls, the SCZ-ID individuals carried 0.045 (0.03 – 0.06, 95% CI) extra 
singleton LoF variants in developmental disorder genes per exome, suggesting 
that around 4% of these cases had a LoF variant that is relevant to their clinical 
presentation. No enrichment in neurodevelopmental disorder genes was 
observed in schizophrenia patients without intellectual disability, suggesting 
that these genes were relevant only for that subset of schizophrenia patients 
(Figure 4, Supplementary Table 4). Notably, even after excluding known 
developmental disorder genes from the set of LoF intolerant genes, we still 
observed an enrichment of rare variants in SCZ-ID patients compared to the 
remaining cases (P = 1 × 10−3; 1.26, 1.08 – 1.47, 95% CI) or to controls (P 
< 5 × 10−7; OR 1.54, 1.31– 1.81, 95% CI; Supplementary Figure 9). Rare variation 
in these genes contributes more to disease risk in the subset of patients with 
both schizophrenia and intellectual disability.  
 
Rare variants confer risk for schizophrenia in individuals without intellectual 
disability 
 
 While rare damaging variants in LoF intolerant genes were most enriched 
in the subset of schizophrenia patients with intellectual disability, we still 
observed a weaker but significant enrichment in individuals with schizophrenia 
for whom we could confirm do not have intellectual disability (P = 5.5 × 10−4; 
1.16, 1.05 – 1.27, 95% CI; Figure 3). Therefore, rare risk variants for 
schizophrenia follow the pattern previously described in autism: concentrated in 
individuals with intellectual disability, but not exclusive to that group. To 
produce a more accurate estimate of the effect of damaging rare variants on 
schizophrenia conditional on their effects on overall cognition, we recalculated 
the enrichment of rare variants in LoF intolerant genes in a subset of 2,161 
schizophrenia cases and 2,398 controls for which data on years of education was 
available and for whom intellectual disability could be excluded (Supplementary 
Figure 8). After controlling for differences in educational attainment (Online 
Methods), individuals with schizophrenia have a 1.26-fold excess of rare variants 
in LoF intolerant genes (P = 2 × 10−6; 1.14 – 1.38, 95% CI). This increase in our 
observed odds ratio is consistent with previous accounts that rare damaging 
variants also affect educational attainment in controls39, thus biasing our 
unconditional estimate. 
Discussion 
  
  
Our integrated analysis of thousands of whole-exome sequences 
demonstrates that rare damaging variants increase risk of schizophrenia both 
with and without co-morbid intellectual disability. While the identification of 
individual genes remains difficult at current samples sizes, we show that the 
burden of damaging de novo mutations, rare SNVs and CNVs in schizophrenia is 
not scattered across the genome but is primarily concentrated in 3,488 genes 
intolerant of loss-of-function variants. This observation is shared with autism, 
intellectual disability, and severe neurodevelopmental disorders32,40. We 
recapitulate enrichment in previously published gene sets, including 
transmission at glutamatergic synapses and translational regulation by FMRP, 
and implicate other gene sets previously linked to autism, intellectual disability, 
and severe developmental disorders. However, we find that all of these gene sets 
share a large number of underlying genes, and are especially enriched with the 
3,488 genes intolerant of LoF variants. These overlaps among gene sets 
originating from very different analyses, as well as the subtleties of how they are 
defined, suggest caution in interpreting biological explanations from observed 
enrichments. 
 
We jointly analyzed the case-control SNV data with information on 
cognitive function for 2,971 patients, and find that LoF variants disrupting genes 
associated with severe developmental disorders are disproportionately found in 
individuals with schizophrenia with co-morbid intellectual disability, with 4% of 
these cases having a single LoF variant that is relevant to their clinical 
presentation. Even after excluding variants in known developmental disorder 
genes, rare variants contribute a greater degree to schizophrenia risk in the SCZ-
ID subgroup of patients than the remaining schizophrenia population. These 
results show that some of these genetic perturbations have clear manifestations 
in childhood, and that rare risk variants in schizophrenia are particularly 
associated with co-morbid intellectual disability. Our observations are consistent 
with results in autism in which rare risk variants are associated with intellectual 
disability22,23,28.  Notably, a weaker but still significant rare variant burden was 
observed in schizophrenia patients without cognitive impairment, and this signal 
persists even after controlling for educational attainment. Together, these results 
demonstrate that rare variants have different contributions to schizophrenia risk 
depending on the degree of cognitive impairment. Importantly, they do not 
simply confer risk for a small subset of patients but contribute to disease 
pathogenesis more broadly.   
 
Our study supports the observation that genetic risk factors for 
psychiatric and neurodevelopmental disorders do not follow clear diagnostic 
boundaries. Coding variants disrupting the same genes, and quite possibly, the 
same biological processes, increase risk for a range of phenotypic manifestation. 
This clinically variable presentation is reminiscent of LoF variants in SETD1A 
and 11 large copy number variant syndromes, previously shown to confer risk 
for schizophrenia in addition to other prominent developmental defects16,18. It is 
possible that these genes contain an allelic series of variants conferring 
gradations of risk. A recent schizophrenia GWAS meta-analysis demonstrated 
that the common variant association signal was similarly enriched in LoF 
intolerant genes41, suggesting that schizophrenia risk genes may be perturbed by 
  
common variants of subtle effects and disrupted by rare variants of high 
penetrance in the population. This possibility is also supported by the overlap in 
at least some of the pathways affected by both rare and common variation, such 
as chromatin remodeling. However, the most common deletion in the 22q11.2 
locus and a recurrent two base deletion in SETD1A are associated with both 
schizophrenia and more severe neurodevelopmental disorders, suggesting the 
same variants can also confer risk for a range of clinical features18,42,43. 
Ultimately, it may prove difficult to clearly partition patients genetically into 
subtypes with similar clinical features, especially if genes and variants 
previously thought to cause well-characterized Mendelian disorders can have 
such varied outcomes. This pattern is consistent with the hypothesis that LoF 
variants in genes under genic constraint result in a spectrum of 
neurodevelopmental outcomes with the burden of mutations highest in 
intellectual disability and least in schizophrenia, corresponding to a gradient of 
neurodevelopmental pathology indexed by the degree of cognitive impairment, 
age of onset, and severity4.  
 
Despite the complex nature of genetic contributions to risk of 
schizophrenia, it is notable that across study design (trio or case-control) and 
variant class (SNVs or CNVs), risk loci of large effect are concentrated in a small 
subset of genes. Previous rare variant analyses in other neurodevelopmental 
disorders, such as autism, have successfully integrated information across de 
novo SNVs and CNVs to identify novel risk loci23. As sample sizes increase, meta-
analyses leveraging the shared genetic risk across study designs and variant 
types, including those we did not consider here, such as classical recessive 
inheritance, will be similarly well powered to identify additional risk genes in 
schizophrenia. 
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Figure captions 
 
Figure 1: Analysis workflow. Data sets are shown in blue, statistical methods 
and analysis steps are shown in green, and results (figures and tables) from the 
analysis are shown in orange. A: Enrichment analyses in 1,766 gene sets using 
the entire rare variant data set. B: Enrichment analyses in LoF intolerant and 
developmental disorder genes in the subset of cases with information on 
cognitive function. ID: intellectual disability; SCZ: schizophrenia; SCZ-ID: 
schizophrenia patients with intellectual disability.  
Figure 2: Enrichment of schizophrenia rare variants in genes intolerant of loss-
of-function variants. A: Schizophrenia cases compared to controls for rare SNVs 
and indels; B: Rates of de novo mutations in schizophrenia probands compared 
to control probands; C: Case-control CNVs. P-values shown were from the test of 
LoF enrichment in A, LoF enrichment in B, and all CNVs enrichment in C. Error 
bars represent the 95% CI of the point estimate. LoF intolerant: 3,448 genes with 
near-complete depletion of truncating variants in the ExAC database; Rest: the 
remaining genes in the genome with pLI < 0.9; Damaging missense: missense 
variants with CADD phred > 15. Asterisk: P < 1 x 10-3. 
 
Figure 3: Enrichment of rare loss-of-function variants in LoF intolerant genes in 
schizophrenia cases stratified by information on cognitive function compared to 
controls. The P-values shown were calculated using the variant threshold 
method comparing LoF burden between the corresponding cases and controls. 
Error bars represent the 95% CI of the point estimate. Damaging missense: 
missense variants with CADD phred > 15. 
 
Figure 4: Enrichment of rare loss-of-function variants in known severe 
developmental disorder genes in schizophrenia cases stratified by information 
on cognitive function compared to controls. The P-values shown were calculated 
using the variant threshold method comparing LoF burden between the 
corresponding cases and controls. Error bars represent the 95% CI of the point 
estimate. Damaging missense: missense variants with CADD phred > 15. 
 
  
Table 1: Gene sets enriched for rare coding variants conferring risk for schizophrenia at FDR < 1%. The effect sizes and corresponding 
P-values from enrichment tests of each variant type (case-control SNVs, DNM, and case-control CNVs) are shown for each gene set, along 
with the Fisher’s combined P-value (Pmeta) and the FDR-corrected Q-value (Qmeta). We only show the most significant gene set if there are 
multiple ones from the same data set or biological process (see Supplementary Table 1 for all 1,766 gene sets). Ngenes: number of genes 
in the gene set; Est: effect size estimate and its lower and upper bound assuming a 95% CI; DNM: de novo mutation.
Name Ngenes EstSNV 
95% CI  
of EstSNV 
PSNV EstDNM 
95% CI  
of EstDNM 
PDNM EstCNV 
95% CI  
of EstCNV 
PCNV Pmeta Qmeta 
ExAC LoF intolerant 
genes 
(pLI > 0.9) 
3488 1.24  1.16-1.31 < 5.0 x 10-7 1.36  1.1-1.68 0.0067 1.21  1.15-1.28 0.00026 < 3.60 x 10-10 4.30 x 10-7 
Dominant, diagnostic 
DDG2P genes, in which 
LoF variants result in 
developmental disorders 
with brain abnormalities 
156 1.42  1.07-1.88 0.011 4.18  2.21-8.03 0.00073 1.92  1.54-2.39 0.0016 2.30 x 10-6 0.00067 
Sanders et al. autism risk 
genes (FDR < 10%) 
66 1.28  0.97-1.69 0.0095 3.96  1.65-9.94 0.019 2.21  1.75-2.79 0.00033 9.50 x 10-6 0.0017 
Darnell et al. targets of 
FMRP 
790 1.24  1.13-1.36 8.5 x 10-6 1.31 0.83-2.09 0.17 1.32  1.2-1.47 0.0032 9.30 x 10-7 0.00038 
Cotney et al. CHD8-
targeted promoters (hNSC 
and human brain tissue) 
2920 1.09  1.02-1.16 0.0008 1.77 1.36-2.31 0.00025 1.11  1.05-1.18 0.027 1.10 x 10-6 0.00038 
G2CDB: mouse cortex 
post-synaptic density 
consensus 
1527 1.20  1.11-1.3 2.5 x 10-6 1.57  1.06-2.33 0.028 1.04  0.96-1.11 0.32 3.90 x 10-6 0.00097 
Weynvanhentenryck et al. 
CLIP targets of RBFOX 
967 1.21  1.11-1.33 4.8 x 10-5 1.84  1.21-2.8 0.0085 1.07  0.98-1.17 0.2 1.30 x 10-5 0.002 
NMDAR network (defined 
in Purcell et al.) 
61 1.66 1.09-2.54 0.0061 5.60  2.06-16.09 0.017 2.46 1.78-3.4 0.0028 3.70 x 10-5 0.0044 
GOBP: chromatin 
modification 
(GO:0016568) 
519 1.29  1.13-1.49 0.00018 2.26  1.32-3.94 0.0099 1.12  0.99-1.28 0.18 4.20 x 10-5 0.0046 
  
Supplementary Table captions 
 
Supplementary Table 1: Full results from enrichment analyses of 1,766 gene 
sets. The P-values from enrichment tests of each variant type (case-control SNVs, 
DNM, and case-control CNVs) are shown for each gene set, along with the 
Fisher’s combined P-value (Pmeta) and the FDR-corrected Q-value (Qmeta). Ngenes: 
number of genes in the gene set; SNV: single nucleotide variants from whole-
exome data; DNM: de novo mutations. 
 
Supplementary Table 2: Gene sets enriched for rare coding variants conferring 
risk for schizophrenia at FDR < 5%. The effect sizes and corresponding P-values 
from enrichment tests of each variant type (case-control SNVs, DNM, and case-
control CNVs) are shown for each gene set, along with the Fisher’s combined P-
value (Pmeta) and the FDR-corrected Q-value (Qmeta). Ngenes: number of genes in 
the gene set; Est: effect size estimate and its lower and upper bound assuming a 
95% CI; SNV: single nucleotide variants from whole-exome data; DNM: de novo 
mutations. 
 
Supplementary Table 3: Results from enrichment analyses of FDR < 5% gene 
sets, conditional on brain-expressed and ExAC LoF intolerant genes.  We restrict 
enrichment analyses to genes that reside in two different background gene sets, 
one defined on brain-enriched expression in GTeX, and the second on genic 
constraint (ExAC LoF intolerant genes), and determined if gene sets with FDR < 
5% in the meta-analysis still had significance above the specific background. The 
P-values from enrichment tests of each variant type (case-control SNVs, DNM, 
and case-control CNVs) are shown for each gene set, along with the Fisher’s 
combined P-value (Pmeta). SNV: single nucleotide variants from whole-exome 
data; DNM: de novo mutations 
 
Supplementary Table 4: Results from enrichment analyses of rare loss-of-
function variants in LoF intolerant genes and developmental disorder genes 
comparing schizophrenia cases stratified by information on cognitive function 
and matched controls. Each comparison is defined in the Table, and the P-values 
shown were calculated using the variant threshold method comparing LoF 
burden between the corresponding case and baseline samples. Ncase: number of 
case samples; Ncomparison: number of comparison samples; Estimates: effect size 
estimate and its lower and upper bound assuming a 95% CI. 
Online Methods 
Sample collections  
 
The ascertainment, data production, and quality control of the 
schizophrenia case-control whole-exome sequencing data set had been 
described in detail in an earlier publication18. Briefly, the data set was composed 
of schizophrenia cases recruited as part of eight collections in the UK10K 
sequencing project, and matched population controls from non-psychiatric arms 
of the UK10K project, healthy blood donors from the INTERVAL project, and five 
  
Finnish population studies. The UK10K data set was combined and analyzed 
with published data from a Swedish schizophrenia case-control study35. The data 
production, quality control, and analysis of the case-control CNV data set was 
described in an earlier publication29. The schizophrenia cases were recruited as 
part of the CLOZUK and CardiffCOGS studies, which consisted of both 
schizophrenia individuals taking the antipsychotic clozapine and a general 
sample of cases from the UK. Matched controls were selected from four publicly 
available non-psychiatric data sets.  All samples were genotyped using Illumina 
arrays, and processed and called under the same protocol. Sanger-validated de 
novo mutations identified through whole exome-sequencing in seven published 
studies of schizophrenia parent-proband trios were aggregated and re-annotated 
for enrichment analyses13,44–49. A full description of each trio study, including 
sequencing and capture technology and sample recruitment was previously 
described18.  
Sample and variant quality control 
 
We jointly called each case data set with its nationality-matched controls, 
and excluded samples based on contamination, coverage, non-European 
ancestry, and excess relatedness18. A number of empirically derived filters were 
applied at the variant and genotype level, including filters on GATK VQSR, 
genotype quality, read depth, allele balance, missingness, and Hardy-Weinberg 
disequilibrium18. After variant filtering, the per-sample transition-to-
transversion ratio was ~3.2 across the entire data set, as expected for 
populations of European ancestry50. For the case-control CNV analysis, we 
similarly excluded samples based on excess relatedness, and only CNVs 
supported by more than 10 probes and greater than 10 kilobases in size were 
retained to ensure high quality calls. All de novo mutations in our study had been 
validated using Sanger sequencing.  
 
We used the Ensembl Variant Effect Predictor (VEP) version 75 to 
annotate all variants (SNVs and CNVs) according to Gencode v.19 coding 
transcripts. We defined frameshift, stop gained, splice acceptor, and donor 
variants as loss-of-function (LoF), and missense or initiator codon variants with 
the recommended CADD Phred score cut-off of greater than 15 as damaging 
missense51. A gene was annotated as disrupted by a deletion if part of its coding 
sequence overlapped the copy number event. We more conservatively defined 
genes as duplicated only if the entire canonical transcript of the gene overlapped 
with the duplication event.  
 
Statistical tests of the case-control exome data used case-control 
permutations within each population (UK, Finnish, Swedish) to generate 
empirical P-values to test hypotheses. No genome-wide inflation was observed in 
burden tests of individual genes18. In the curated set of de novo mutations, we 
observed the expected exome-wide number of synonymous mutations given 
gene mutation rates from previously validated models24, suggesting variant 
calling was generally unbiased across Gencode v.19 coding genes. Lastly, the 
case-control CNV data set had been previously analyzed for burden of CNVs 
affecting individual genes, and enrichment analyses in targeted gene sets7,29.  
  
Rare variant gene set enrichment analyses 
Case-control enrichment burden tests For the case-control SNV data set, we 
performed permutation-based gene set enrichment tests using an extension of 
the variant threshold method30. This method assumed that variants with a MAF 
below an unknown threshold 𝑇 were more likely to be damaging than variants 
with a MAF above 𝑇, and this threshold was allowed to differ for every gene or 
pathway tested. To consider different possible values for threshold 𝑇, a gene or 
gene set test statistic 𝑡(𝑇) was calculated for every allowable 𝑇, and the 
maximum test-statistic, or 𝑡max, was selected. The statistical significance of 𝑡max 
was evaluated by permuting phenotypic labels, and calculating 𝑡max from the 
permuted data such that different values of 𝑇 could be selected following each 
permutation. In Price et al., 𝑡(𝑇) was defined as the 𝑧-score calculated from 
regressing the phenotype on the sum of the allele counts of variants in a gene 
with MAF < 𝑇. We extended this method to test for enrichment in gene sets by 
regressing schizophrenia status on the total number of damaging alleles in the 
gene set of interest with MAF < 𝑇 (𝑋𝑖𝑛,𝑇) while correcting for the total number of 
damaging alleles genome-wide with MAF < 𝑇 (𝑋𝑎𝑙𝑙,𝑇). 𝑋𝑎𝑙𝑙,𝑇  controlled for 
exome-wide differences between schizophrenia cases and controls, ensuring any 
significant gene set result was significant beyond baseline differences. 𝑡(𝑇) was 
defined as the 𝑡-statistic testing if the regression coefficient of 𝑋𝑖𝑛,𝑇 deviated 
from 0. We then calculated 𝑡(𝑇) for all observed thresholds below a minor allele 
frequency of 0.1%, and selected the maximum value for the 𝑡max based on the 
observed data. To calculate a null distribution for 𝑡max, we performed two 
million case-control permutations within each population (UK, Finnish, and 
Swedish) to control for batch and ancestry, and calculated 𝑡max for each 
permuted sample while allowing 𝑇 to vary. The 𝑃-value for each gene set was 
calculated as the fraction of the two million permuted samples that had a greater 
𝑡max than what was observed in the unpermuted data. The odds ratio and 95% 
confidence interval of each gene set was calculated using a logistic regression 
model, regressing schizophrenia status on 𝑋𝑖𝑛 while controlling for total number 
of variants genome-wide (𝑋𝑎𝑙𝑙) and population (UK, Finnish, and Swedish). 
Unlike gene set 𝑃-values which were calculated using permutation across 
multiple frequency thresholds, the odds ratios an d 95% CI were calculated using 
only variants observed once in our data set (allele count of 1) to ensure they 
were comparable between tested gene sets. 
CNV logistic regression We adapted a logistic regression framework described in 
Raychaudhuri et al. and implemented in PLINK to compare the case-control 
differences in the rate of CNVs overlapping a specific gene set while correcting 
for differences in CNV size and total genes disrupted7,19,31. We first restricted our 
analyses to coding deletions and duplications, and tested for enrichment using 
the following model:  
log (
𝑃𝑖,case
1−𝑃𝑖,case
) = 𝛽0 + 𝛽1𝑠𝑖 + 𝛽2𝑔all + 𝛽3𝑔in + 𝜖, 
where for individual i, pi is the probability they have schizophrenia i, si is the 
total length of CNVs, gall is the total number of genes overlapping CNVs, and gin is 
the number of genes within the gene set of interest overlapping CNVs. It has been 
  
shown that 𝛽1 and 𝛽2 sufficiently controlled for the genome-wide differences in 
the rate and size of CNVs between cases and control, while 𝛽3 captured the true 
gene set enrichment above this background rate7,19,31. For each gene set, we 
reported the one-sided P-value, odds ratio, and 95% confidence interval of 𝛽3.  
Weighted permutation-based sampling of de novo mutations For each variant class 
of interest, we first determined the total number of de novo mutations observed in 
the 1,077 schizophrenia trios. We then generated 2 million random samples with 
the same number of de novo mutations, weighting the probability of observing a 
mutation in a gene by its estimated mutation rate. The baseline gene-specific 
mutation rates were obtained using the method described in Samocha et al. and 
adapted to produce LoF and damaging missense rates for each Gencode v.19 gene. 
These mutation rates adjusted for both sequence context and gene length, and 
were successfully applied in the primary analyses of large-scale exome sequencing 
of autism and severe developmental disorders with replicable results23,32,40. For 
each gene set, one-sided enrichment P-values were calculated as the fraction of 
two million random samples that had a greater or equal number of de novo 
mutations in the gene set of interest than what is observed in the 1,077 trios. The 
effect size of the enrichment was calculated as the ratio between the number of 
observed mutations in the gene set of interest and the average number of 
mutations in the gene set across the two million random samples. We adapted a 
method in Fromer et al. to calculate 95% credible intervals for the enrichment 
statistic13. We first generated a list of one thousand evenly spaced values between 
0 and ten times the point estimate of the enrichment. For each value, the mutation 
rates of genes in the gene set of interest were multiplied by that amount, and 
50,000 random samples of de novo mutations were generated using these 
weighted rates. The probability of observing the number of mutations in the gene 
set of interest given each effect size multiplier was calculated as the fraction of 
samples in which the number of mutations in the gene set is the same as the 
observed number in the 1,077 trios. We normalized the probabilities across the 
1,000 values to generate a posterior distribution of the effect size, and calculated 
the 95% credible interval using this empirical distribution.  
 
Combined joint analysis Gene set P-values calculated using the case-control SNV, 
case-control CNV, and de novo data were meta-analyzed using Fisher’s combined 
probability method with df = 6 to provide a single test statistic for each gene set. 
We corrected for the number of gene sets tested in the discovery analysis (n = 
1,776) by controlling the false discovery rate (FDR) using the Benjamini-Hochberg 
approach, and reported only results with a q-value of less than 5%.  
 
Description of gene sets 
 
The full list of tested gene sets is found in Supplementary Table 1, and a 
detailed description is provided in the Supplementary Note. Briefly, we tested all 
gene sets with more than 100 genes from five public pathway databases. We 
additionally tested additional gene sets selected based on biological hypotheses 
about schizophrenia risk, and genome-wide screens investigating rare variants 
in intellectual disability, autism spectrum disorders, and other 
neurodevelopmental disorders. All gene identifiers were mapped to the 
  
GENCODE v.19 release, and all non-coding genes were excluded. A total of 1,766 
gene sets were included in our analysis. 
Selection of allele frequency thresholds and consequence severity  
 
For the case-control whole-exome data, we applied an extension of the 
variant threshold model (described above). With this method, we tested 
damaging variants at a number of frequency thresholds without specifying an a 
priori MAF cut-off. All thresholds below a MAF of 0.1% observed in our data 
were tested, and we assessed statistical significance by permutation testing. For 
all the whole-exome data (case-control and trio data), we restricted our analyses 
to loss-of-function variants. These variants have a clear and severe predicted 
functional consequence in that they putatively cause a single-copy loss of a gene. 
Furthermore, this class of variants had been demonstrated to have the strongest 
genome-wide enrichment between cases and controls across 
neurodevelopmental and psychiatric disorders18,32,40. When selecting MAF cut-
offs for case-control CNVs, we found that while the bulk of the test statistics were 
not inflated, the tail of gene set P-values were dramatically inflated even when 
testing for enrichment in the random gene sets (Supplementary Figure 1). This 
inflation in the tail of the Q-Q plot was driven in part by very large (overlapping 
more than 10 genes), more common (MAF between 0.1% and 1%) CNVs 
observed mainly in cases or controls. Some of these, such as the known 
syndromic CNVs, likely harbored true risk genes. However, because these CNVs 
were highly recurrent in cases and depleted in controls, and disrupted a large 
number of genes, any gene set that included even a single gene within these 
CNVs would appear to be significant, even after controlling for total CNV length 
and genes overlapped. To ensure our model was well calibrated and its P-values 
followed a null distribution for random gene sets, we explored different 
frequency and size thresholds, and conservatively restricted our analysis to copy 
number events overlapping less than seven genes (excluding the largest 10% of 
CNVs) with MAF < 0.1% (Supplementary Figure 1). Our main conclusions 
remained unchanged even if we selected a more stringent (excluding the largest 
15% of CNVs) or less stringent (excluding the largest 5% of CNVs) size threshold. 
 
Robustness of enrichment analyses 
 
We uniformly sampled genes from the genome (as defined by Gencode 
v.19) to generate random gene sets with the same size distribution as the 1,776 
gene sets in our discovery analysis. For each random set, we calculated gene set 
P-values for the case-control SNV data, case-control CNV data, and de novo data 
using the appropriate method and frequency cut-offs across all variant classes. A 
Q-Q plot was generated using P-values from enrichment tests of each data set 
and variant type. Reassuringly, we observed null distributions in all such Q-Q 
plots (Supplementary Figure 3).  
 
Comparison of de novo enrichment with broader neurodevelopmental 
disorders 
 
  
We aggregated and re-annotated de novo mutations from four studies: 
1,113 severe DD probands40, 4,038 ASD probands23,32, and 2,134 control 
probands28,32. We used the Poisson exact test to calculate differences in de novo 
rates in constrained genes between schizophrenia, ASD, and DD and controls. 
Counts in each functional class (synonymous, missense, damaging missense, and 
LoF) were tested separately, and the one-sided P-value, rate ratio, and 95% CI of 
each comparison were reported and plotted in Figure 2, Supplementary Figure 4 
and 5.  
 
Conditional analyses 
 
In each of the three methods we used for gene set enrichment, we 
restricted all variants analyzed to those that reside in the background gene list, 
and tested for an excess of rare variants in genes shared between the gene set of 
interest (K) and the background list (B). Brain-enriched genes from GTEx, and 
the ExAC LoF intolerant genes (pLI > 0.9) were used as backgrounds (see above). 
For the case-control SNV data, we modified the variant threshold method to 
regress schizophrenia status on the total number of damaging alleles in genes 
present in both the gene set of interest and the background gene set (𝐾 ∩ 𝐵), 
while correcting for the total number of damaging alleles in the set of all 
background genes (𝐵). The logistic regression model for the case-control CNV 
data was modified to:  
log (
𝑃𝑖,case
1−𝑃𝑖,case
) = 𝛽0 + 𝛽1𝑠𝑖 + 𝛽2𝑔𝐵 + 𝛽3𝑔𝐾 ∩ 𝐵 + 𝜖, 
where gB is the total number of background genes overlapping a CNV, and 𝑔𝐾 ∩ 𝐵 is 
the number of genes in the intersection of the gene set of interest and the 
background list overlapping a CNV. Finally, we determined the total number of 
de novo mutations within the background gene list observed in the 1,077 
schizophrenia trios, and generated 2 million random samples with the same 
number of de novo mutations. For each gene set, one-sided enrichment P-values 
were calculated as the fraction of two million random samples that had a greater 
or equal number of de novo mutations in genes in 𝐾 ∩  𝐵 than what is observed in 
the 1,077 trios. Gene set P-values were combined using Fisher’s method. We 
restricted our conditional enrichment analysis to gene sets with q-value < 5% in 
the discovery analysis, and adjusted for multiple testing using Bonferroni 
correction (P = 0.00071, or 0.05/67 tests; see Supplementary Table 3). 
 
Rare variants and cognition in schizophrenia 
 Within the UK10K study, 97 individuals from the MUIR collection were 
given discharge diagnoses of mild learning disability and schizophrenia (ICD-8 
and -9). The recruitment guidelines of the MUIR collection were described in 
detail in a previous publication52. In brief, evidence of remedial education was a 
prerequisite to inclusion, and individuals with pre-morbid IQs below 50 or above 
70, severe learning disabilities, or were unable to give consent were excluded. 
The Schizophrenia and Affective Disorders Schedule-Lifetime version (SADS-L) 
in people with mild learning disability, PANSS, RDC, and DSM-III-R, and St. Louis 
Criterion were applied to all individuals to ensure that any diagnosis of 
  
schizophrenia was robust. Using the clinical information provided alongside the 
Swedish and Finnish case-control data sets, we identified additional 182 
schizophrenia individuals who were similarly diagnosed with intellectual 
disability, for a total of 279 individuals. 
Cognitive testing and educational attainment data available for a subset of 
samples were used identify schizophrenia individuals without cognitive 
impairment. For 502 individuals from the Cardiff collection in the UK10K study, 
we acquired their pre-morbid IQ as extrapolated from National Adult Reading 
Test (NART), and identified 412 individuals for analysis after excluding all 
individuals with predicted pre-morbid IQ of less than 85 (or below one standard 
deviation of the population distribution for IQ). We additionally acquired 
information on educational attainment in 54 schizophrenia individuals in the 
UK10K London collection, and retained 27 individuals without intellectual 
disability and who completed at least 12 years of schooling. Lastly, the California 
Verbal Learning Test was conducted on 124 Finnish schizophrenia individuals 
sequenced as part of UK10K, and a composite score was generated from 
measures of verbal and visual working memory, verbal abilities, 
visuoconstructive abilities, and processing speed. All individuals with intellectual 
disability had been excluded from cognitive testing. Within this set of samples, 
we additionally excluded any individuals who ranked in the lowest decile in 
CVLT composite score, and retained 92 individuals for analysis. According to 
these criteria, we identified 531 of 697 schizophrenia individuals from the UK 
and Finnish data sets with cognitive data as not having intellectual disability. We 
additionally acquired data on educational attainment for the Swedish 
schizophrenia cases and controls from the Swedish National Registry. After 
excluding individuals with intellectual disability, we identified 1,527 
schizophrenia individuals who did not complete secondary school (less than 12 
years of schooling), and 634 schizophrenia individuals who completed at least 
compulsory and upper secondary schooling (at least 12 years of schooling). The 
last group with the greatest educational attainment and without intellectual 
disability was defined as cases without cognitive impairment. In the Swedish 
sample, 49.4% of control samples had lower educational attainment than the 
634 individuals with schizophrenia defined as having no cognitive impairment, 
suggesting that our definition was sufficiently strict. In total, combining the UK, 
Finnish, and Swedish data, we identified 1,165 schizophrenia individuals without 
cognitive impairment. 
Using the variant threshold method, we tested for differences in rare LoF 
burden between the three case groups (intellectual disability, did not complete 
secondary school, no cognitive impairment) against controls. We restricted these 
analyses to three gene sets (LoF intolerant genes, genes in which LoF variants 
are diagnostic for severe developmental disorders, and LoF intolerant genes 
after excluding severe developmental disorders genes), and adjusted for multiple 
testing using Bonferroni correction (P = 0.0038, or 0.05/13 tests). 
Supplementary Table 4 enumerated all the statistical tests performed. To 
estimate the per-exome excess of rare singleton (defined as having an allele 
count of one in our data set) LoF variants in cases compared to controls, we 
regressed 𝑋𝑖𝑛 (the number of LoF variants in the gene set of interest) on case 
status (0 or 1) while controlling for 𝑋𝑎𝑙𝑙 (the total number of LoF variants 
  
genome-wide) and population (UK, Finnish, and Swedish). The effect size and 
95% CI of the regression coefficient of case status predictor were reported.  
Data Availability 
 
Sequence data and processed VCFs for the UK10K project were deposited into 
the European Genome-phenome Archive (EGA) under study accession code 
EGAO00000000079. The processed VCFs from the Swedish case-control study 
were deposited in dbGAP under accession code (phs000473.v1.p1). Rare variant 
counts, and gene-level association results from combining the whole-exome 
sequencing data sets were described in a previous publication18 and were made 
available on the PGC results and download page 
(https://www.med.unc.edu/pgc/results-and-downloads). 
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